Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance-Reference-Cited by-同舟云学术

Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance

Published:2007-01 Issue:1 Volume:47 Page:64-103
ISSN:0065-2571
Container-title:Advances in Enzyme Regulation
language:en
Short-container-title:Advances in Enzyme Regulation

Author:

McCubrey James A.,Steelman Linda S.,Franklin Richard A.,Abrams Steven L.,Chappell William H.,Wong Ellis W.T.,Lehmann Brian D.,Terrian David M.,Basecke Jorg,Stivala Franca,Libra Massimo,Evangelisti Camilla,Martelli Alberto M.

Publisher

Elsevier BV

Subject

Cancer Research,Genetics,Molecular Biology,Molecular Medicine

Reference268 articles.

1. Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase;Abe;J Biol Chem,1996

2. Transient and sustained ERK phosphorylation and nuclear translocation in growth control;Adachi;J Cell Physiol,2002

3. Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders;Aggerholm;Eur J Haematol,2000

4. Inhibition of caspase-9 by phosphorylation at Thr125 by ERK MAP kinase;Allan;Nat Cell Biol,2003

5. Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1;Aplin;J Cell Biol,2001

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of epidermal growth factor receptors as a key clinical target against cancer;Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy;2024

2. Inhibition of SGK1 potentiates the anticancer activity of PI3K inhibitor in NSCLC cells through modulation of mTORC1, p‑ERK and β‑catenin signaling;Biomedical Reports;2023-10-13

3. Multi-Omics Analysis of NCI-60 Cell Line Data Reveals Novel Metabolic Processes Linked with Resistance to Alkylating Anti-Cancer Agents;International Journal of Molecular Sciences;2023-08-26

4. Identification of the Anticancer Potential of Vitamin B17 via Targeting Raf-1 and Autophagy-related Gene Expression;MIDDLE EAST J CANCER;2023

5. Cardiomyocyte hyperplasia and immaturity but not hypertrophy are characteristic features of patients with RASopathies;Journal of Molecular and Cellular Cardiology;2023-05